Abstract
1. The bioavailability and disposition of 882C87, an anti-varicella zoster virus (VZV) agent, have been investigated in healthy young and elderly volunteers. 2. The mean bioavailability of a 200 mg tablet was 21.1% in the young (range 13.3-33.0%, n = 10) and 24.6% in the elderly (range 14.4-38.4%, n = 8), which is sufficient to achieve plasma concentrations well above the IC50 for anti-VZV activity. 3. Plasma concentrations of 882C87 after 50 mg i.v. were higher in the elderly than in the young, associated with a significantly longer half-life (13.7 vs 11.8 h) and decreased renal clearance (0.11 vs 0.14 ml min-1 kg-1) and total clearance (0.15 vs 0.17 ml min-1 kg-1). 4. After intravenous administration, the main route of elimination of 882C87 was renal with 81.6% recovered unchanged in urine in the young and 71.2% in the elderly. The pyrimidine base, 5-propynyluracil (5-PU) was unquantifiable in plasma and only present in trace amounts in urine. 5. After oral administration to four healthy volunteers, only 17% of a dose of [14C]-882C87 was recovered unchanged in urine and 58% as 5-PU, with total recovery in urine accounting for 86% of the dose. There was a lag of 4-12 h before the appearance of 5-PU in plasma, peak concentrations were one-third to a half those of 882C87. The data suggest that 5-PU is formed from unabsorbed 882C87 in the gut lumen and then absorbed and excreted in urine. 6. 882C87 is a potential once daily treatment for shingles.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Ashida N., Ijichi K., Watanabe Y., Machida H. Metabolism of 5'-ether prodrugs of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil in rats. Biochem Pharmacol. 1993 Dec 14;46(12):2201–2207. doi: 10.1016/0006-2952(93)90610-9. [DOI] [PubMed] [Google Scholar]
- Buick A. R., Sheung C. T. Determination of 1-(beta-D-arabinofuranosyl)-5-(1-propynyl)-uracil and a metabolite, 5-propynyluracil, in plasma using ASTED (automated sequential trace enrichment of dialysates) combined, on-line, with high-performance liquid chromatography. J Chromatogr. 1993 Jul 23;617(1):65–70. doi: 10.1016/0378-4347(93)80422-z. [DOI] [PubMed] [Google Scholar]
- Burke B. L., Steele R. W., Beard O. W., Wood J. S., Cain T. D., Marmer D. J. Immune responses to varicella-zoster in the aged. Arch Intern Med. 1982 Feb;142(2):291–293. [PubMed] [Google Scholar]
- Cockcroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. doi: 10.1159/000180580. [DOI] [PubMed] [Google Scholar]
- HOPE-SIMPSON R. E. THE NATURE OF HERPES ZOSTER: A LONG-TERM STUDY AND A NEW HYPOTHESIS. Proc R Soc Med. 1965 Jan;58:9–20. doi: 10.1177/003591576505800106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Huff J. C., Bean B., Balfour H. H., Jr, Laskin O. L., Connor J. D., Corey L., Bryson Y. J., McGuirt P. Therapy of herpes zoster with oral acyclovir. Am J Med. 1988 Aug 29;85(2A):84–89. [PubMed] [Google Scholar]
- McKendrick M. W., McGill J. I., White J. E., Wood M. J. Oral acyclovir in acute herpes zoster. Br Med J (Clin Res Ed) 1986 Dec 13;293(6561):1529–1532. doi: 10.1136/bmj.293.6561.1529. [DOI] [PMC free article] [PubMed] [Google Scholar]
- O'Brien J. J., Campoli-Richards D. M. Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1989 Mar;37(3):233–309. doi: 10.2165/00003495-198937030-00002. [DOI] [PubMed] [Google Scholar]